dr. petrylak on pivotal parp inhibitor trials in mcrpc with dna repair mutations
Published 3 years ago • 167 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
0:25
daniel p. petrylak, md, on the role of dna repair gene mutations in metastatic urothelial carcinoma
-
10:36
parp inhibitor trial updates
-
1:05
dr. petrylak on psma adc for patients with mcrpc
-
3:49
the role of targeting dna repair mutations in advanced prostate cancer
-
3:34
future of parp inhibitors in mcrpc
-
8:12
asco gu 2020: dr. petrylak discusses exciting prostate cancer and bladder cancer data
-
1:21
dr. petrylak explains prostate cancer clinical trial difficulties
-
12:24
the role of targeting dna repair with parp
-
0:56
dr. petrylak on ongoing investigations of checkpoint inhibition in bladder cancer
-
0:47
dr. petrylak on the recent developments in prostate cancer
-
0:47
dr. daniel petrylak describes the clinical investigation of prostvac in prostate cancer
-
8:47
treatment of metastatic crpc
-
6:18
checkpoint inhibitor therapy in prostate cancer
-
1:23
dr. petrylak on a phase ii trial of psma adc in taxane-treated mcrpc
-
1:11
dr. daniel petrylak on orteronel (tak-700) plus docetaxel in prostate cancer
-
1:24
dr. dorff discusses the use of parp inhibitors in prostate cancer
-
1:32
dr. chang discusses the use of parp inhibitors in prostate cancer
-
47:27
parp inhibitors: a breakthrough in cancer therapy?
-
1:01
dr. petrylak on novel imaging modalities in prostate cancer